New injectable sits at the center of this dementia and brain health question.
A single injection of an experimental drug called lepodisiran, developed by Eli Lilly, reduced a dangerous form of cholesterol to nearly undetectable levels for close to a full year in clinical trials. In Phase 2 results presented at the American College of Cardiology’s 2025 conference, one dose of lepodisiran lowered lipoprotein(a) — a genetically inherited cardiovascular risk factor — by an average of 93.9% over the first six months, and levels remained 88.5% below baseline even at the one-year mark. For the roughly one in five people worldwide who carry elevated Lp(a) and face heightened risk of heart attack, stroke, and vascular dementia, this is a development worth paying close attention to.
What makes this particularly relevant for brain health is the growing body of evidence linking cardiovascular risk factors to cognitive decline. High cholesterol, poor vascular health, and conditions like atherosclerosis don’t just threaten the heart — they compromise blood flow to the brain, accelerating the kind of damage that leads to vascular dementia and may worsen Alzheimer’s disease progression. A drug that can durably knock out a major cardiovascular risk factor with a single annual injection could reshape prevention strategies for both heart disease and dementia. This article covers how lepodisiran works and where it stands in clinical development, how it compares to already-approved injectable cholesterol drugs like Leqvio and Lerochol, the emergence of a one-time gene-editing cholesterol treatment from Verve Therapeutics, and what all of this means for people concerned about long-term brain health.
Table of Contents
- How Does an Injectable Cholesterol Drug Work After Just One Dose a Year?
- What Is Lipoprotein(a), and Why Should People Worried About Dementia Care?
- Gene Editing for Cholesterol — The Promise of a One-Time Treatment
- How Lepodisiran Compares to Already-Approved Injectable Cholesterol Drugs
- Safety Concerns and What We Still Don’t Know
- What This Means for Dementia Prevention Strategies
- The Future of Cardiovascular-Based Dementia Prevention
- Conclusion
- Frequently Asked Questions
How Does an Injectable Cholesterol Drug Work After Just One Dose a Year?
Lepodisiran belongs to a class of drugs called small interfering RNAs, or siRNAs. These are short, synthetic strands of genetic material designed to silence a specific gene inside liver cells. In this case, lepodisiran targets the LPA gene, which instructs the liver to produce lipoprotein(a). Once the drug reaches liver cells, it essentially shuts down the manufacturing line for Lp(a), and because the silencing effect persists for months, a single injection can keep levels suppressed for the better part of a year. In the Phase 1 trial published in JAMA in 2023, a single 608 mg injection reduced Lp(a) to undetectable levels by day 29, and those levels remained unmeasurable through day 281. The Phase 2 ALPACA trial, with results published in the New England Journal of Medicine, confirmed and extended these findings. At the 400 mg dose, patients saw an average Lp(a) reduction of 93.9% over the first 180 days. Even more striking, a single dose still held Lp(a) at 53.4% below baseline at 540 days — a year and a half later.
Patients who received a second dose at the six-month mark achieved a 94.8% reduction. To put this in practical terms, someone whose Lp(a) level puts them at two to three times the normal cardiovascular risk could, with one or two injections per year, bring that specific risk factor down to a level that is essentially negligible. It is important to understand what lepodisiran does not do. It targets Lp(a) specifically, not LDL cholesterol, which is the number most people see on their standard lipid panel. Lp(a) is a distinct particle that carries its own independent risk, and until now, there has been no FDA-approved drug to lower it. Statins don’t touch it. Diet and exercise barely move it. For people with genetically high Lp(a), lepodisiran could fill a gap that has been empty for decades.
What Is Lipoprotein(a), and Why Should People Worried About Dementia Care?
Lipoprotein(a) is often called the “stealth” cholesterol because standard blood tests don’t measure it, most doctors don’t order it, and many patients have never heard of it. Yet roughly 20% of the global population carries Lp(a) levels high enough to significantly increase their risk of heart attack, stroke, and aortic valve disease. Unlike LDL cholesterol, Lp(a) levels are almost entirely determined by genetics. You inherit your Lp(a) level, and without pharmacological intervention, it stays essentially fixed throughout your life. The connection to brain health is vascular. Elevated Lp(a) promotes atherosclerosis — the buildup of plaque in arteries — and when that process affects the blood vessels supplying the brain, the consequences can include small vessel disease, silent strokes, and vascular dementia.
Research has shown that midlife cardiovascular risk factors are among the strongest modifiable predictors of late-life cognitive decline. A person who has a heart attack at 55 due to high Lp(a) is also a person whose brain has likely been experiencing reduced blood flow for years before that event. However, it is worth noting a limitation: while the cardiovascular connection to dementia is well established, lepodisiran has not been studied specifically for its effects on cognitive outcomes. The Phase 3 ACCLAIM-Lp(a) trial currently enrolling approximately 16,700 patients is designed to determine whether lowering Lp(a) reduces cardiovascular events like heart attacks and strokes. Cognitive endpoints are not part of that trial’s primary design. So while there is strong biological plausibility that reducing Lp(a) could protect brain health, direct proof is still some distance away.
Gene Editing for Cholesterol — The Promise of a One-Time Treatment
While lepodisiran requires annual or semiannual dosing, a more radical approach is emerging from Verve Therapeutics. Their treatment, VERVE-102, is an in vivo base-editing therapy — meaning it uses a form of gene editing to permanently alter the PCSK9 gene directly in a patient’s liver cells. If it works as hoped, this would be a one-and-done treatment: a single infusion that permanently lowers LDL cholesterol with no further doses ever needed. Early results from the Phase 1b HEART-2 trial, announced in April 2025, were encouraging. Among 14 patients with heterozygous familial hypercholesterolemia and premature coronary artery disease, a single infusion at the 0.6 mg/kg dose produced a mean LDL-C reduction of 53%, with the best individual response reaching a 69% reduction. The treatment was well tolerated, with no treatment-related serious adverse events. One patient experienced a moderate infusion reaction that resolved with acetaminophen.
Verve expects final dose-escalation and durability data in the second half of 2025, with a Phase 2 trial planned to begin by late 2025. The distinction between lepodisiran and VERVE-102 is fundamental. Lepodisiran silences a gene temporarily — the effect wears off over months, which is why repeat dosing is needed. VERVE-102 edits the DNA itself, permanently changing the genetic instructions in liver cells. The upside is obvious: treat once, benefit for life. The downside is equally clear. A permanent edit cannot be easily reversed if something goes wrong, and the long-term safety of in vivo gene editing in humans is still unknown. This is a technology in its earliest clinical stages, and it will take years of follow-up data before anyone can speak confidently about its safety profile.
How Lepodisiran Compares to Already-Approved Injectable Cholesterol Drugs
Lepodisiran is not yet FDA-approved, but it enters a space where injectable cholesterol treatments already exist. The most relevant comparison is Leqvio (inclisiran), a Novartis siRNA drug that received FDA approval in December 2021. Leqvio also works by silencing gene activity in the liver, but it targets PCSK9 rather than Lp(a), and it reduces LDL cholesterol by approximately 50% on top of statins. Leqvio requires three injections in the first year — an initial dose, a booster at three months, and then dosing every six months thereafter. It is the closest thing currently available to a “twice a year” cholesterol shot. Another new entrant is Lerochol (lerodalcibep-liga), a once-monthly self-administered PCSK9 inhibitor that has received FDA approval and is expected to be available in the United States in spring 2026.
In clinical trials, Lerochol lowered LDL-C by more than 60% in high-risk patients. It is a subcutaneous injection that patients can give themselves at home, similar to insulin, but on a monthly rather than daily schedule. The tradeoffs between these drugs come down to target, frequency, and approval status. Leqvio and Lerochol both lower LDL cholesterol through PCSK9 inhibition and are approved for use now or very soon. Lepodisiran targets Lp(a), a different lipid particle that no approved drug currently addresses, but it remains in clinical trials. For a patient with both high LDL and high Lp(a), the future might involve a combination: a PCSK9 inhibitor for LDL plus lepodisiran for Lp(a), potentially managed with just a handful of injections per year rather than daily pills.
Safety Concerns and What We Still Don’t Know
The safety data for lepodisiran so far has been reassuring, but it comes with an important caveat: the sample sizes are still small, and the follow-up periods are still short relative to what a lifelong treatment requires. In the Phase 2 ALPACA trial, there were no drug-related serious adverse events. Up to 10% of patients experienced mild, transient injection-site reactions — pain or redness at the injection site — that resolved without treatment. These are the kinds of side effects that most patients and physicians would consider highly acceptable. But lepodisiran’s mechanism — silencing a gene in liver cells — raises questions that only large-scale, long-duration trials can answer. What happens after five, ten, or twenty years of annual Lp(a) suppression? Lp(a) exists in human biology for a reason, even if that reason is not entirely understood.
Some researchers have hypothesized that Lp(a) may play a role in wound healing or infection response. Reducing it to undetectable levels for years on end is, from an evolutionary biology standpoint, an experiment without precedent. The Phase 3 ACCLAIM-Lp(a) program, with its enrollment of approximately 16,700 patients, is the largest Lp(a) outcomes trial ever conducted and should provide much more robust safety and efficacy data — but those results are still years away. There is also the question of access and cost. siRNA drugs are not cheap. Leqvio, the already-approved siRNA cholesterol drug, has a list price of roughly $6,500 per year in the United States, and insurance coverage has been inconsistent. If lepodisiran follows a similar pricing trajectory, it may initially be accessible primarily to patients in well-resourced health systems, even if it eventually proves to be one of the most impactful cardiovascular drugs in a generation.
What This Means for Dementia Prevention Strategies
For people focused on brain health — whether they are caring for a loved one with dementia or trying to reduce their own risk — the emergence of injectable cholesterol drugs adds a new layer to prevention planning. The established guidance remains important: manage blood pressure, stay physically active, maintain social engagement, treat hearing loss, avoid excessive alcohol, and control blood sugar. But cardiovascular risk factor management, including cholesterol, is increasingly recognized as central to brain health strategy.
If you or a family member have a history of early heart disease, stroke, or have been told your cholesterol is “genetic” and resistant to lifestyle changes, asking your doctor to check Lp(a) levels is a reasonable step right now — even before lepodisiran reaches the market. Knowing your Lp(a) level establishes a baseline and identifies whether this particular risk factor is relevant to your situation. For those with elevated Lp(a), enrollment in the ACCLAIM-Lp(a) Phase 3 trial may even be an option worth discussing with a cardiologist.
The Future of Cardiovascular-Based Dementia Prevention
The next five years could fundamentally change how we think about dementia prevention. If the ACCLAIM-Lp(a) trial demonstrates that lowering Lp(a) reduces strokes and cardiovascular events, the logical follow-up will be studies examining whether that same reduction translates into preserved cognitive function. Meanwhile, if VERVE-102’s gene-editing approach proves durable and safe through Phase 2 and Phase 3 trials, we may eventually face a scenario where a single treatment in middle age permanently eliminates a major vascular risk factor for dementia.
None of this replaces the basics — sleep, exercise, cognitive engagement, social connection — but it does mean that the pharmacological toolkit for protecting the aging brain is expanding beyond anything available even a few years ago. The shift from daily pills to annual injections to potential one-time genetic treatments reflects a broader move in medicine toward interventions that work with human behavior rather than against it. For anyone who has watched a loved one struggle with a daily medication regimen while navigating cognitive decline, the value of a treatment that works after a single dose needs no explanation.
Conclusion
Lepodisiran represents a genuine advance: a single injection that can suppress a dangerous, genetically determined cholesterol particle by more than 90% for nearly a year. Alongside the already-approved Leqvio and Lerochol, and the emerging gene-editing approach of VERVE-102, injectable cholesterol treatments are rapidly expanding the options available for cardiovascular risk reduction. For brain health specifically, these developments matter because vascular damage is one of the most significant — and most preventable — contributors to cognitive decline and dementia.
The practical takeaway right now is straightforward. Ask your doctor about Lp(a) testing if you have a personal or family history of heart disease or stroke. Stay informed about the results of the ACCLAIM-Lp(a) Phase 3 trial, which will be the definitive test of whether lowering Lp(a) translates into fewer cardiovascular events. And recognize that while lepodisiran is not yet available outside of clinical trials, the trajectory of injectable cholesterol medicine is moving unmistakably toward less frequent dosing, more durable effects, and — if the science holds — meaningful protection for both the heart and the brain.
Frequently Asked Questions
Is lepodisiran FDA-approved?
No. Lepodisiran is still in clinical trials. The Phase 3 ACCLAIM-Lp(a) program is currently enrolling approximately 16,700 patients and is the largest Lp(a) outcomes trial ever conducted. FDA approval, if it comes, is likely several years away.
How is Lp(a) different from regular LDL cholesterol?
Lp(a) is a distinct lipoprotein particle that carries its own independent cardiovascular risk. Unlike LDL, Lp(a) levels are almost entirely determined by genetics and are not significantly affected by diet, exercise, or statin therapy. Most standard lipid panels do not include Lp(a), so many people with dangerously high levels are unaware of it.
Can injectable cholesterol drugs help prevent dementia?
There is strong biological plausibility but no direct clinical proof yet. Cardiovascular risk factors like high cholesterol are well-established contributors to vascular dementia and may worsen Alzheimer’s disease. Drugs that reduce these risk factors could protect brain health, but specific studies measuring cognitive outcomes with these new injectables have not yet been completed.
What injectable cholesterol drugs are currently available?
Leqvio (inclisiran), approved in December 2021, is given twice yearly after an initial dose and three-month booster, reducing LDL-C by about 50%. Lerochol (lerodalcibep-liga) is a once-monthly self-injection that lowers LDL-C by more than 60% and is expected to be available in the US in spring 2026. Both target PCSK9 to lower LDL cholesterol.
What is VERVE-102 and how is it different from lepodisiran?
VERVE-102 is a gene-editing therapy from Verve Therapeutics that permanently alters the PCSK9 gene in liver cells. Unlike lepodisiran, which temporarily silences a gene and requires repeat dosing, VERVE-102 makes a permanent DNA edit — potentially a one-time treatment for life. It is in Phase 1b trials and showed a mean LDL-C reduction of 53% from a single infusion.
Should I ask my doctor about Lp(a) testing?
Yes, especially if you have a personal or family history of premature heart disease, stroke, or aortic valve disease. Lp(a) testing requires a simple blood test but is not included in standard lipid panels. Knowing your level can help you and your doctor assess a cardiovascular risk factor that might otherwise go undetected.
You Might Also Like
- New PCSK9 Inhibitor Lowers Cholesterol With Just 2 Doses Per Year
- New Lung Cancer Drug Works in Patients With a Rare Mutation
- New Testosterone Drug Prevents Breast Cancer Recurrence in Some Women
For more, see NIH MedlinePlus — dementia.
